Aduhelm is the first drug to be approved by the FDA that claims to treat Alzheimer's disease rather ...
Read moreWe’ve prepared a summary of our key market access blogs and news articles from the second quarter ...
Read moreThe EU is known for the variety of market access rules its member states impose. We’re here to gui...
Read moreA dive into the complex and expensive world of gene therapy pricing and access.
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe HST process is a method for evaluating medicines and treatments specifically indicated for ultra...
Read moreClinical evidence relating to therapeutic efficacy and safety is one of the most valuable criteria o...
Read moreOne year after the first lockdown was announced in the UK we take a brief look at trends and changes...
Read moreThe European Parliament and Council negotiators reached a provisional agreement on a joint health te...
Read moreBiosimilars could be launching a lot earlier in the UK than the EU thanks to new guidance, improved ...
Read more